| Ytd | 13.41% | |
| 1y | 1.09% |
| Open | 1.40 | Prev Close | 1.41 | Low | 1.40 | High | 1.41 | Mkt Cap | 120.30M |
| Vol | 3.13K | Avg Vol | 465.19K | EPS | -0.40 | P/E | -3.49 | Forward P/E | -2.11 |
| Beta | 2.35 | Short Ratio | 12.59 | Inst. Own | 10.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.29 | 200-d Avg | 1.30 | 1yr Est | 5.50 |
VANI News
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosi
NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic w
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani"), a clinical-stage biopharmaceutical company de
Vivani CEO Adam Mendelsohn, Ph.D., stated, "HREC approval to initiate SLIM-1 in Australia marks
Lake Street analyst Thomas Flaten initiates coverage on Vivani Medical (NASDAQ:VANI) with a Buy r
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.09) per share which beat the analyst c
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage bio
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst co
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical
https://d1io3yog0oux5.cloudfront.net/_8b0e72ba9731939ad4ef3d445345826e/vivanimedical/db/2227/20875/p
Cortigent is a leading developer of brain implant devices based on precision neurostimulation techno
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administrationFirs
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.12) per share which missed the analyst
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data sh
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage bio
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which missed the analyst
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma
ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:V
Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatm
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst co
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma
Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight lo
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for w
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and ma
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-q
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the co
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The compan